Functional assays provide a robust tool for the clinical annotation of genetic variants of uncertain significance

npj Genomic Medicine

Volumn 1, Issue , 2016, Pages

  Woods, Nicholas T ^a   Baskin, Rebekah ^b   Golubeva, Volha ^b   Jhuraney, Ankita ^b,c   De Gregoriis, Giuliana ^d   Vaclova, Tereza ^b,e   Goldgar, David E ^f   Couch, Fergus J ^g   Carvalho, Marcelo Alex ^d,h   Iversen, Edwin S ⁱ   Monteiro, Alvaro N A ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^e Structural Biology and Biocomputing Programme   (Spain)

^f UNIVERSITY OF UTAH   (United States)

^g MAYO CLINIC   (United States)

^h Instituto Federal Do Rio de Janeiro   (Brazil)

ⁱ Duke University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84988953685     PISSN: None     EISSN: 20567944     Source Type: Journal    
DOI: 10.1038/npjgenmed.2016.1     Document Type: Article

References (44)

1. Reich, D. E. & Lander, E. S. On the allelic spectrum of human disease. Trends Genet. 17, 502-510 (2001).
2. MacArthur, D. G. et al. Guidelines for investigating causality of sequence variants in human disease. Nature 508, 469-476 (2014).
3. Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405-424 (2015).
4. Miki, Y. et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266, 66-71 (1994).
5. Millot, G. A. et al. A guide for functional analysis of BRCA1 variants of uncertain significance. Hum. Mutat. 33, 1526-1537 (2012).
6. Iversen, E. S., Couch, F. J., Goldgar, D. E., Tavtigian, S. V. & Monteiro, A. N. A. Computational method to classify variants of uncertain significance using functional assay data with application to BRCA1. Cancer Epidemiol. Biomarkers Prev. 20, 1078-1088 (2011).
7. Yandell, M. et al. Genome-wide analysis of human disease alleles reveals that their locations are correlated in paralogous proteins. PLoS Comput. Biol. 4, e1000218 (2008).
8. Carvalho, M. A. et al. Determination of cancer risk Associated with germ line BRCA1 missense variants by functional analysis. Cancer Res. 67, 1494-1501 (2007).
9. Phelan, C. M. et al. Classification of BRCA1 missense variants of unknown clinical significance. J. Med. Genet. 42, 138-146 (2005).
10. Vallee, M. P. et al. Classification of missense substitutions in the BRCA genes: A database dedicated to Ex-UVs. Hum. Mutat. 33, 22-28 (2012).
11. Lindor, N. M. et al. A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS). Hum. Mutat. 33, 8-21 (2012).
12. Plon, S. E. et al. Sequence variant classification and reporting: Recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum. Mutat. 29, 1282-1291 (2008).
13. Carvalho, R. S. et al. Probing structure-function relationships in missense variants in the carboxy-Terminal region of BRCA1. PloS ONE 9, e97766 (2014).
14. Goldgar, D. E. et al. Integrated evaluation of DNA sequence variants of unknown clinical significance: Application to BRCA1 and BRCA2. Am. J. Hum. Genet. 75, 535-544 (2004).
15. Easton, D. F. et al. A systematic genetic assessment of 1, 433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancerpredisposition genes. Am. J. Hum. Genet. 81, 873-883 (2007).
16. Goldgar, D. E. et al. Genetic evidence and integration of various data sources for classifying uncertain variants into a single model. Hum. Mutat. 29, 1265-1272 (2008).
17. Ng, P. C. & Henikoff, S. Predicting deleterious amino acid substitutions. Genome Res. 11, 863-874 (2001).
18. Adzhubei, I. A. et al. A method and server for predicting damaging missense mutations. Nat. Methods 7, 248-249 (2010).
19. Kircher, M. et al. A general framework for estimating the relative pathogenicity of human genetic variants. Nat. Genet. 46, 310-315 (2014).
20. Schwarz, J. M., Cooper, D. N., Schuelke, M. & Seelow, D. MutationTaster2: mutation prediction for the deep-sequencing age. Nat. Methods 11, 361-362 (2014).
21. Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-Throughput sequencing data. Nucleic Acids Res. 38, e164 (2010).
22. Antoniou, A. C. et al. Breast-cancer risk in families with mutations in PALB2. N. Engl. J. Med. 371, 497-506 (2014).
23. Lupas, A., Van Dyke, M. & Stock, J. Predicting coiled coils from protein sequences. Science 252, 1162-1164 (1991).
24. Sy, S. M., Huen, M. S. & Chen, J. PALB2 is an integral component of the BRCA complex required for homologous recombination repair. Proc. Natl Acad. Sci. USA 106, 7155-7160 (2009).
25. Woods, N. T. et al. Charting the landscape of tandem BRCT domain-mediated protein interactions. Sci. Signal. 5, rs6 (2012).
26. Mohammad, D. H. & Yaffe, M. B. 14-3-3 proteins, FHA domains and BRCT domains in the DNA damage response. DNA Repair (Amst) 8, 1009-1017 (2009).
27. Soutoglou, E. & Misteli, T. Activation of the cellular DNA damage response in the absence of DNA lesions. Science 320, 1507-1510 (2008).
28. Tavtigian, S. V., Byrnes, G. B., Goldgar, D. E. & Thomas, A. Classification of rare missense substitutions, using risk surfaces, with genetic-And molecularepidemiology applications. Hum. Mutat. 29, 1342-1354 (2008).
29. Amberger, J., Bocchini, C. & Hamosh, A. A new face and new challenges for Online Mendelian Inheritance in Man (OMIM(R). Hum. Mutat. 32, 564-567 (2011).
30. Hindorff, L. A. et al. Potential etiologic and functional implications of genomewide association loci for human diseases and traits. Proc. Natl Acad. Sci. USA 106, 9362-9367 (2009).
31. Chin, L., Hahn, W. C., Getz, G. & Meyerson, M. Making sense of cancer genomic data. Genes Dev. 25, 534-555 (2011).
32. Simhadri, S. et al. Male fertility defect associated with disrupted BRCA1-PALB2 interaction in mice. J. Biol. Chem. 289, 24617-24629 (2014).
33. Lee, M. S. et al. Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays. Cancer Res. 70, 4880-4890 (2010).
34. Bouwman, P. et al. A high-Throughput functional complementation assay for classification of BRCA1 missense variants. Cancer Discov. 3, 1142-1155 (2013).
35. Domchek, S. M. et al. Biallelic deleterious BRCA1 mutations in a woman with early-onset ovarian cancer. Cancer Discov. 3, 399-405 (2013).
36. Kato, S. et al. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc. Natl Acad. Sci. USA 100, 8424-8429 (2003).
37. Jhuraney, A. et al. BRCA1 Circos: A visualisation resource for functional analysis of missense variants. J. Med. Genet. 52, 224-230 (2015).
38. Polaczek, P., Putzke, A. P., Leong, K. & Bitter, G. A. Functional genetic tests of DNA mismatch repair protein activity in Saccharomyces cerevisiae. Gene 213, 159-167 (1998).
39. Wielders, E. A. et al. Functional analysis of MSH2 unclassified variants found in suspected Lynch syndrome patients reveals pathogenicity due to attenuated mismatch repair. J. Med. Genet. 51, 245-253 (2014).
40. Ji, H. P. & King, M. C. A functional assay for mutations in tumor suppressor genes caused by mismatch repair deficiency. Hum. Mol. Genet. 10, 2737-2743 (2001).
41. Abkevich, V. et al. Analysis of missense variation in human BRCA1 in the context of interspecific sequence variation. J. Med. Genet. 41, 492-507 (2004).
42. Stucki, M. et al. MDC1 directly binds phosphorylated histone H2AX to regulate cellular responses to DNA double-strand breaks. Cell 123, 1213-1226 (2005).
43. Singh, N. et al. Dual recognition of phosphoserine and phosphotyrosine in histone variant H2A.X by DNA damage response protein MCPH1. Proc. Natl Acad. Sci. USA 109, 14381-14386 (2012).
44. Carvalho, M. A. et al. Analysis of a set of missense, frameshift, and in-frame deletion variants of BRCA1. Mutat Res. 660, 1-11 (2009).